| Theme | Pancreatic Cancer : Up-to-date | |
|---|---|---|
| Title | Clinical Evidence from Postoperative Adjuvant Therapy for Pancreatic Cancer | |
| Publish Date | 2011/01 | |
| Author | Yoshihiro Sakamoto | Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital |
| Author | Tomoo Kosuge | Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital |
| Author | Hideki Ueno | Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital |
| Author | Satoshi Nara | Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital |
| Author | Minoru Esaki | Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital |
| Author | Kazuaki Shimada | Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital |
| [ Summary ] | Clinical evidence to support postoperative adjuvant therapy for pancreatic cancer has recently been established. In the USA, adjuvant chemoradiation therapy is the dominant form of treatment. In Europe and Japan, adjuvant chemotherapy is the primary treatment. In the CONKO-001 and JSAP-02 trials, disease-free survival rates were significantly better in the adjuvant gemcitabine (GEM) group than in the surgery alone group and in the former trial, overall survival rates improved in the GEM group. In the ESPAC-3 trial (a randomized trial comparingadjuvant GEM to 5-FU groups) the survival rates of both groups were similar. However, adverse events were significantly lower in the GEM group than in the 5-FU group. Thus, adjuvant chemotherapy using GEM has been recognized as the standard therapy for pancreatic cancer. Clinical trials of adjuvant therapy are ongoing in Japan | |